Funding section was not complete.
This should have read:
Funding: This study was supported by the Italian Ministry of Health (Ricerca Corrente) 20/1819.
The affected articles are listed in the reference list.
We apologize for these errors.
References
- 1. Burton JO, Coats AJS, Kovesdy CP, Palmer BF, Piña IL, Rosano G, et al. An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum. Eur J Heart Fail. 2022;24:1467–77. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. D'Amario D, Rodolico D, Rosano GMC, Dahlström U, Crea F, Lund LH, et al. Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry. Eur J Heart Fail. 2022;24:871–84. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Bayés‐Genís A, Aimo A, Metra M, Anker S, Seferovic P, Rapezzi C, et al. Head‐to‐head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines. Eur J Heart Fail. 2022;24:916–26. [DOI] [PubMed] [Google Scholar]
- 4. Metra M, Jankowska EA, Pagnesi M, Anker SD, Butler J, Dorigotti F, et al.; AFFIRM‐AHF Investigators . Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial. Eur J Heart Fail. 2022;24:1928–39. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Rosano GMC, Celant S, Olimpieri PP, Colatrella A, Onder G, Di Lenarda A, et al. Impact of the COVID‐19 pandemic on prescription of sacubitril/valsartan in Italy. Eur J Heart Fail. 2022;24:855–60. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Piepoli MF, Adamo M, Barison A, Bestetti RB, Biegus J, Böhm M, et al. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. Eur J Heart Fail. 2022;24:143–68. [DOI] [PubMed] [Google Scholar]
- 7. Anker SD, Ponikowski P, Khan MS, Friede T, Jankowska EA, Fabien V, et al. Responder analysis for improvement in 6‐min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency. Eur J Heart Fail. 2022;24:833–42. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Vukadinović D, Abdin A, Anker SD, Rosano GMC, Mahfoud F, Packer M, et al. Side effects and treatment initiation barriers of sodium–glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta‐analysis. Eur J Heart Fail. 2022;24:1625–32. [DOI] [PubMed] [Google Scholar]
- 9. Butler J, Usman MS, Anstrom KJ, Blaustein RO, Bonaca MP, Ezekowitz JA, et al. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum. Eur J Heart Fail. 2022;24:2029–36. [DOI] [PubMed] [Google Scholar]
- 10. Rosano GMC, Metra M, Volterrani M. The strategic vision of the 2022–2024 mandate – greater involvement of members, young specialists for an HFA community without borders. Eur J Heart Fail. 2022;24:1458–9. [DOI] [PubMed] [Google Scholar]
- 11. Lindberg F, Lund LH, Benson L, Dahlström U, Karlström P, Linde C, et al. Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry. Eur J Heart Fail. 2022;24:2093–104. [DOI] [PMC free article] [PubMed] [Google Scholar]